L-Carnitine Dosage, Reconstitution & Mixing Trends

Explore l-carnitine calculator-entry dose, vial-size, BAC-water and self-reported frequency distributions. Research context is separate from live observations.

Anonymized l-carnitine calculator entries are summarized by each chart's selected period. Frequency responses come from the separate vial-duration feature. Inputs are not verified administrations or unique people.

What L-Carnitine Is

L-carnitine (levocarnitine) is a naturally occurring nutrient that helps transport fatty acids into mitochondria for energy, most often sourced for fat-metabolism and exercise research. It is FDA-approved as Carnitor for carnitine deficiency and is widely used in sports nutrition. It is supplied in several forms — injectable solution, capsules, or powder.[1][2]

L-carnitine is the substrate for the carnitine-palmitoyltransferase (CPT) shuttle: long-chain acyl-CoA is converted to acyl-carnitine by CPT1 on the outer mitochondrial membrane, transported across the inner membrane via the carnitine-acylcarnitine translocase, and reconverted to acyl-CoA by CPT2 in the matrix for β-oxidation.[1] Without adequate tissue carnitine, long-chain fatty acid oxidation cannot proceed efficiently. The acetyl-L-carnitine variant has additional CNS-active properties as a methyl donor and acetylcholine precursor.[3]

FDA-approved indications include primary carnitine deficiency (a rare inborn error of metabolism) and secondary carnitine deficiency in end-stage renal disease patients on hemodialysis.[2] Off-label research areas include cardiac ischemia, peripheral arterial disease (intermittent claudication, where propionyl-L-carnitine has the strongest evidence base), male infertility, exercise performance, and fat oxidation.[3][4] The Stephens / Brass body of work establishes that meaningful changes in muscle carnitine content require sustained insulin co-administration (carbohydrate), not bolus injection alone.[5][6]

FDA-approved (Carnitor / levocarnitine) for primary carnitine deficiency and for ESRD-related carnitine deficiency. Available OTC as oral L-carnitine, L-carnitine L-tartrate, and acetyl-L-carnitine dietary supplements. Off-label injectable use is widespread in sports / fat-loss contexts.

L-Carnitine Research Sources

L-Carnitine Dosing Context

L-Carnitine has a reported half-life of ~15 hours. The pharmacokinetic reference models an interval of once daily; this is not a measured community cadence or a dosing recommendation. A roughly half-day half-life means daily dosing tops up a partially-retained pool, with modest buildup toward a stable level over a few days. Pharmacokinetic source: L-carnitine clinical pharmacokinetic literature. It is catalogued under Weight Loss on WPA.

L-Carnitine Community Calculator Data

126 L-Carnitine reconstitution calculations have been logged by the WPA community.

This is the lifetime header population. Each chart and its associated analysis below use their own selected period and denominator; frequency responses are a separate cohort.

These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.

WPA Analysis

L-Carnitine Research Background and Calculator Data

L-Carnitine (international name levocarnitine) is a quaternary ammonium compound synthesized endogenously from lysine and methionine and obtained additionally through dietary intake (primarily red meat). Its biological role is unusually well-defined: it is the obligate substrate for the carnitine palmitoyltransferase 1 and 2 (CPT-1 / CPT-2) shuttle that transports long-chain fatty acyl-CoA molecules across the inner mitochondrial membrane, where they enter beta-oxidation and become available for ATP generation. Without adequate intramitochondrial carnitine, long-chain fatty acid oxidation fails — which is why primary carnitine deficiency (a defect in the OCTN2 carnitine transporter) and the various secondary carnitine deficiency states (chronic dialysis, valproate-induced depletion, mitochondrial fatty acid oxidation disorders) produce skeletal myopathy, cardiomyopathy, and hypoketotic hypoglycemia. The molecule is one of the few compounds on this entire site that is FDA-approved — marketed as CARNITOR (Sigma-Tau / Leadiant) for both oral and intravenous use in primary and secondary carnitine deficiency, with separate labeled indications in end-stage renal disease patients on hemodialysis. The published literature is extensive: cardiovascular outcomes (the contested Wang et al. (2013) TMAO line of work raising long-term safety questions), ergogenic effects in exercise, male fertility, hepatic steatosis, and a long history in metabolic and weight-management clinics where injectable L-carnitine is used off-label as a fat-mobilization adjunct.

Research background is separate from the calculator observations below. Calculator entries do not establish administration, safety, effectiveness, or the reasons for an input.

WPA DOSING INSIGHT

Dose and Frequency Calculator Inputs

The summaries use each chart's own period and, for frequency responses, its dose filter. Separate cohorts must not be combined into a protocol.

WPA RECONSTITUTION INSIGHT

Vial Size and BAC Water Calculator Inputs

Vial-size and BAC-water observations describe separate input distributions, not purchases or verified preparations. Separate modal inputs do not establish a joint protocol.

Illustrative arithmetic, not an observed combination or recommendation: 500mg mixed with 10mL gives 50mg/mL. A 50mg target corresponds to 1mL.

These figures come from anonymized WPA peptide calculator sessions.

All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.